AFT Pharmaceuticals confirms dual-listing plans to fund R&D, global growth

Paul McBeth
Thu, 08 Oct 2015

By Paul McBeth Oct. 9 (BusinessDesk) - AFT Pharmaceuticals, the Auckland-based drugs developer and reseller, wants to list in Australia and New Zealand, raising funds to speed up the development of products to sell in other countries. The company is considering an initial public offering on the NZX and ASX, hiring First NZ Capital as sole lead manager, it said in a statement, without indicating how much money it wants to raise. The funds raised will go towards completing clinical product development and introducing those drugs into foreig...
Economy
BRIAN GAYNOR: Aluminium smelter reaches use by date
Brian Gaynor | Sat, 11 Jul 2020

The negative market reaction to Rio Tinto’s announcement that it was winding down the Tiwai Point aluminium smelter was overdone, particularly for investors with long-term perspectives. The smelter...

Markets
MARKET CLOSE: NZ shares fall as energy sector sell-off continues
Dan Brunskill | Fri, 10 Jul 2020

New Zealand shares fell as energy stocks declined for a second day following the announcement Rio Tinto’s New Zealand aluminium smelter will close. Chorus led the market lower on the risk of more r...

Finance
Metlifecare and EQT enter new $6 per share takeover agreement
Jenny Ruth | Fri, 10 Jul 2020

Metlifecare said it has entered into a new scheme of arrangement with Swedish company EQT to buy all its shares for $6 each, a dollar less than the earlier deal EQT had repudiated, but only four of th...

The role of private equity in the wake of COVID-19

As local covid-19 restrictions ease, a new business cycle is beginning in New Zealand.

Sponsored: What’s next for the future of the office?

Think everyone is going to keep working from home? No so fast, says Milford Asset Management.